News: Simtuzumab

We provide the latest news and info on Simtuzumab


The Pharma Letter (registration)

Strike two: Gilead chalks up another setback for top pipeline prospect simtuzumab
FierceBiotech
Gilead has racked up its second straight setback on simtuzumab, scrapping a mid-stage study for idiopathic pulmonary fibrosis after a data monitoring group concluded that the drug wasn't working as expected. The drug, which blocks the LOXL2 enzyme, has ...
Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary FibrosisBusiness Wire (press release)
Gilead stops Phase II trial of simtuzumabThe Pharma Letter (registration)
Gilead Sciences (GILD) Terminates Phase 2 Study of Simtuzumab in IPFStreetInsider.com
San Francisco Business Times (blog) -ValueWalk -Wall Street Journal
all 108 news articles »

Published on Monday 25th of April 2016 02:27:00 AM Read more...


The Pharma Letter (registration)

Gilead presents positive data on liver fibrosis treatments
The Pharma Letter (registration)
The findings, which were presented at the International Liver Congress 2016 in Barcelona, Spain, support the continuation of studies of simtuzumab, GS-4997 and GS-9674, investigational compounds for the treatment of NASH and PSC. NASH is a serious ...
Gilead Sciences (GILD) Announces Presentation of New Data for NASH, PSC TreatmentsStreetInsider.com

all 3 news articles »

Published on Monday 25th of April 2016 02:27:00 AM Read more...


Gilead Presents New Data Highlighting Progress in Liver Fibrosis
Business Wire (press release)
Simtuzumab is a monoclonal antibody that is selective for lysyl oxidase-like-2 (LOXL2), an extracellular matrix enzyme that promotes fibrosis via the cross-linkage of collagen fibers. Gilead is evaluating simtuzumab for the treatment of fibrosis in ...

and more »

Published on Monday 25th of April 2016 02:27:00 AM Read more...


Pulmonary Fibrosis News

Phase II Trial for Gilead's IPF Therapy Simtuzumab Terminated After DMC Recommendation
Pulmonary Fibrosis News
Gilead Sciences, Inc. recently announced in a press release that it is stopping its RAINIER Phase II clinical trial testing the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF), noting that the ...

Published on Monday 25th of April 2016 02:27:00 AM Read more...


Bidness ETC

Gilead Sciences, Inc May Want Intercept Pharmaceuticals as its Next Small Purchase
Bidness ETC
Of these, simtuzumab is most promising and currently being tested in mid-stage trials. The company is also working on an experimental drug, GS-4997, separately and in combination with simtuzumab in Phase 2 NASH trials, while another candidate for the ...

and more »

Published on Monday 25th of April 2016 02:27:00 AM Read more...


Gilead (GILD) Simtuzumab Advancement in NASH an 'Incremental Positive', Jefferies Says
StreetInsider.com
Jefferies analyst Brian Abrahams said they have confirmed that the interim 48-week futility analysis for antifibrotic pipeline antibody simtuzumab in NASH has been completed and the ph.II studies are continuing. The sees this as an incremental positive ...

and more »

Published on Monday 25th of April 2016 02:27:00 AM Read more...


Gilead Halts Study of Simtuzumab in Patients With Pulmonary Fibrosis
Managed Care magazine
Gilead Sciences has announced that the company is stopping its mid-stage trial of the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis. The decision follows an analysis of unblinded efficacy and safety ...

and more »

Published on Monday 25th of April 2016 02:27:00 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts